Media Highlights
HudsonAlpha genetic counselor discusses whether women should be tested for breast cancer gene mutations
News Outlet:
The Huntsville Times and WHNT
Date published:
May 14, 2013 
HUNTSVILLE, AL -- Actress Angelina Jolie underwent a preventive double mastectomy after learning she carries a mutation of the BRCA1 gene, which sharply increases her risk of developing breast cancer and ovarian cancer. She learned this after a test showed that she was 87 percent likely to develop breast cancer. This has left many women wondering if they should be tested for this genetic abnormality as well.
Kelly East, a genetic counselor at HudsonAlpha, says 5-10 percent of all breast cancers are hereditary.
HudsonAlpha researcher Jian Han, M.D., Ph.D., teams up with UAH researcher to identify invasive plant species
News Outlet:
Newswise
Date published:
April 28, 2013 
HUNTSVILLE, Ala. — University of Alabama in Huntsville assistant biology professor Dr. Leland Cseke and HudsonAlpha Institute for Biotechnology researcher Dr. Jian Han have joined forces to identify invasive plant species that are sneaking into the United States because they look just like desirable crops or ornamentals.
HUNTSVILLE, Alabama -- Interested in learning -- quickly -- what some of Alabama's smartest minds are working on in biotechnology? Block out April 26 from 3-6 p.m. on your calendar when theHudsonAlpha Institute for Biotechnology showcases its resident companies, speed-dating style.
HUNTSVILLE, ALA. -- The genetic research that goes on at HudsonAlpha Institute for Biotechnology can seem complicated, the stuff of lofty science journals. A photography exhibit the institute recently commissioned, however, shows that work in a different light. It's Aidan, who recently lost his first tooth, and Brandon, who has a great sprinkle of freckles across his face. It's Sarah with her wide smile and brown eyes.
HUNTSVILLE, Ala. -- EGEN, Inc. today announced that it has recently initiated a Phase I clinical trial of its novel immunotherapy agent, EGEN-001, in combination with PEGylated liposomal Doxorubicin or Lipodox for the treatment of recurrent ovarian cancer. The EGEN-sponsored trial is conducted by a network of researchers led by Gynecologic Oncology Group (GOG) at member institutions under an agreement between the GOG and EGEN, Inc. Premal Thaker, M.D., M.S., of Washington University School of Medicine, is the Study Chair for the trial.
Huntsville, AL (PRWEB) January 29 -- TransOMIC technologies announced today that it has partnered with Clontech (a Takara Bio company) to launch the MGC premier™ Tagged ORF collections for gene and protein analysis. Over 40,000 human, mouse and rat genes are represented in these new genome-scale ORF collections, making transOMIC technologies the largest provider of gene content for protein expression.Jeremy Schmutz receives cotton biotechnology award
News Outlet:
PR Newswire
Date published:
January 16, 2013 
NEW YORK, Jan. 17, 2013 -- As part of the recent Plant and Animal Genomic Conference held in San Diego, Calif., Dr. Don Jones of Cotton Incorporated presented the 2012 Cotton Biotechnology Award to five outstanding researchers that were instrumental in mapping the cotton genome. The diverse and talented team, composed of Dr. Andrew Paterson, Dr. Jonathan Wendel, Mr. Jeremy Schmutz, Dr. Dan Peterson and Dr. Dan Rokhsar, led the collaborative international effort to complete the first "gold standard" Gossypium genome sequence. 
HUNTSVILLE, Alabama - The Rocket City's battle against bulge is getting serious. On Tuesday, Mayor Tommy Battle announced an expanded 
No one has done more to push Alabama’s image as a leader in biotechnology than Huntsville’s Jim Hudson, one of the founders of the HudsonAlpha Institute for Biotechnology.
CFD Research Corporation has been awarded a $1.3 million grant from the National Institutes of Health to develop their novel in vitro tumor model. SynVivo-Tumor replicates the tumor microenvironment with physiologically and morphologically realistic microvasculature including endothelial cell-lined leaky vessels and 3D solid tumors. Tumor drug delivery is a complex phenomenon affected by several elements in addition to physico-chemical properties.